SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.7925

Change

+0.02 (+2.79)%

Market Cap

N/A

Volume

0.03M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-7.37 (-1.68%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.47 (-0.26%)

USD 65.38B
ARGX argenx NV ADR

-18.43 (-3.29%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-3.33 (-1.23%)

USD 32.75B
SMMT Summit Therapeutics PLC

-0.65 (-2.57%)

USD 27.07B
ONC BeiGene, Ltd.

-8.52 (-3.65%)

USD 26.35B
RPRX Royalty Pharma Plc

-0.53 (-1.59%)

USD 18.40B
INSM Insmed Inc

-2.04 (-3.01%)

USD 11.84B
INCY Incyte Corporation

-0.04 (-0.07%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-1.59 (-2.59%)

USD 11.29B

ETFs Containing SLRX

SRET Global X SuperDividend® .. 3.43 % 0.59 %

-0.07 (-0.34%)

USD 0.18B
MORT VanEck Mortgage REIT Inco.. 3.17 % 0.42 %

+0.08 (+-0.34%)

USD 0.26B
REM iShares Mortgage Real Est.. 3.15 % 0.48 %

+0.18 (+-0.34%)

USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.93% 16% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.93% 16% F 8% B-
Trailing 12 Months  
Capital Gain -79.78% 19% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.78% 19% F 7% C-
Trailing 5 Years  
Capital Gain -99.52% 6% D- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.52% 6% D- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 93.15% 85% B 93% A
Dividend Return 93.15% 85% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 893.53% 12% F 4% F
Risk Adjusted Return 10.42% 64% D 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.